Clinical perspective, offered as context rather than as advice.
6 month update on cardiovascular risk: down 39 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.
chris_chi24 said:6 month update on cardiovascular risk: down 39 lbs, off blood pressure meds, A1C normalized.
I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.
My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.
11 months later: down 48 lbs, off metoprolol, A1C from 7.6% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.
chris_chi24 said:6 month update on cardiovascular risk: down 39 lbs, off blood pressure meds, A1C normalized.
Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].
This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultschris_chi24 said:6 month update on cardiovascular risk: down 39 lbs, off blood pressure meds, A1C normalized.
Thank you for spelling out the reasoning rather than just the conclusion. Taking it to my next appointment.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.